Fleury SA
BOVESPA:FLRY3

Watchlist Manager
Fleury SA Logo
Fleury SA
BOVESPA:FLRY3
Watchlist
Price: 14.49 BRL -5.85% Market Closed
Market Cap: 7.9B BRL

Fleury SA
Investor Relations

Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace.

In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 7, 2025
AI Summary
Q3 2025

Revenue Growth: Gross revenue for the quarter reached BRL 2.4 billion, up 11.5% year-over-year, driven by strong B2C performance and supported by both organic and inorganic factors.

B2C Outperformance: The B2C business unit grew 12.9% organically and 16% including acquisitions, showing robust demand and brand strength.

M&A Activity: Two major acquisitions—Laboratorio Sao Lucas and Femme—were announced, aligned with the group's strategy to expand its presence, especially in women’s health and mid-tier segments.

Stable Margins: EBITDA grew 11.5% to BRL 599.4 million, maintaining a stable margin of 27.4% compared to last year.

Net Income Dip: Net income was BRL 184.9 million, down 3% year-over-year, mainly due to higher depreciation and increased financial expenses from higher interest rates.

Cash Generation: Operating cash flow was strong at BRL 718.5 million, up 28.6% year-over-year, with a high cash conversion rate of 91%.

Financial Discipline: Leverage remained low at 1.0x net debt/EBITDA, and the company’s capital structure supports continued growth and high dividend payout.

Key Financials
Gross Revenue
BRL 2.4 billion
EBITDA
BRL 599.4 million
EBITDA Margin
27.4%
Net Income
BRL 184.9 million
Net Margin
8.4%
Operating Cash Flow
BRL 718.5 million
Cash Conversion Rate
91%
Leverage (Net Debt/EBITDA)
1.0x
Return on Invested Capital (ROIC)
16.5%
CapEx
BRL 126 million
B2C Organic Growth
12.9%
B2B Revenue
BRL 511.6 million
Novos Elos/Health Platform Revenue
BRL 204.3 million
Gross Profit
BRL 615.8 million
Gross Profit Margin
28.1%
Operating Expenses
BRL 249.5 million
Effective Tax Rate
22.8%
Earnings Call Recording
Other Earnings Calls

Management

Ms. Jeane Mike Tsutsui
CEO & President of Executive Board
No Bio Available
Mr. Jose Antonio de Almeida Filippo
CFO, Investor Relations Officer & Member of Executive Board
No Bio Available
Mr. Claudio Almeida Prado
Executive Director of New Links & Member of Executive Board
No Bio Available
Mr. Edgar Gil Rizzatti
Medical, Technical & Process Executive Director and Member of Executive Board
No Bio Available
Mr. Roberto Santoro Meirelles
L2L & Operations Support Officer and Member of Executive Board
No Bio Available
Mr. Fernando Aguiar Camargo
Secretary
No Bio Available

Contacts

Address
SAO PAULO
Sao Paulo
Av. General Valdomiro de Lima, 508, Jabaquara
Contacts
+551150351986
www.fleury.com.br